Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Unrelated Donor Stem Cell Transplantation

The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

ejection fraction
cancer
umbilical cord blood transplantation
allogeneic transplantation
bone marrow failure
  • 73 views
  • 08 Nov, 2020
  • 1 location
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with a T cell depleted graft, the infusion of naturally occurring regulatory T cells with conventional T cells (T cell add back) in pre-defined doses and ratios will reduce the incidence of acute graft vs host disease while augmenting the …

cancer
hematologic malignancy
antibiotics
leukapheresis
nucleic acid
  • 35 views
  • 27 Aug, 2021
  • 1 location
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCR+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk …

  • 0 views
  • 20 Mar, 2021
  • 1 location
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

hydroxyurea
myeloproliferative syndromes
hematologic malignancy
fludarabine
chronic myeloid leukemia
  • 0 views
  • 25 Jan, 2021
  • 9 locations
Allo HSCT Using RIC for Hematological Diseases

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus …

ejection fraction
thrombocytopenia
blast cells
renal impairment
neutrophil count
  • 27 views
  • 31 May, 2021
  • 1 location
Protocol For Genomically Profiling Collecting Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic

hematologic malignancy
acute leukemia
leukemia
chronic leukemia
  • 0 views
  • 26 Jul, 2021
  • 2 locations
COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

The classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the …

essential thrombocythemia
thrombocytosis
myelofibrosis
polycythemia vera
polycythemia
  • 0 views
  • 06 Jul, 2021
  • 1 location